DNLI
HEALTHCAREDenali Therapeutics Inc
$20.41+1.49 (+7.88%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving DNLI Today?
No stock-specific AI insight has been generated for DNLI yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$12.58$23.77
$20.41
Fundamentals
Market Cap$3.1B
P/E Ratio—
EPS$-2.97
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding158.7M
DNLI News
22 articles- Denali Therapeutics Reports First Quarter 2026 Financial Results and Business HighlightsYahoo Finance·May 7, 2026
- Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug ApprovalMotley Fool·May 5, 2026
- Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns RightsYahoo Finance·May 4, 2026
- Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive?Yahoo Finance·May 2, 2026
- What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest inYahoo Finance·Apr 29, 2026
- Bernstein Upgrades Takeda Pharmaceutical (TAK) to OutperformYahoo Finance·Apr 23, 2026
- DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?Yahoo Finance·Apr 17, 2026
- A Look At Takeda Pharmaceutical (TSE:4502) Valuation After Mixed Pipeline News On DNL593 And ZasocitinibYahoo Finance·Apr 8, 2026
- Denali Stock Falls as Partner Takeda Ends Collaboration DealYahoo Finance·Apr 7, 2026
- Takeda Exits Dementia Drug Partnership With Denali Therapeutics - Here's WhyBenzinga·Apr 6, 2026
- Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)Yahoo Finance·Apr 3, 2026
- Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.Yahoo Finance·Apr 1, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
- Denali Therapeutics (DNLI) Is Down 13.9% After First BBB-Crossing Hunter Therapy Wins FDA Nod - What's ChangedYahoo Finance·Mar 30, 2026
- Denali Wins FDA Nod for Hunter Syndrome Drug, Stock UpYahoo Finance·Mar 26, 2026
- Denali Therapeutics Wins FDA Accelerated Approval for AVLAYAH in Hunter Syndrome, Eyes Launch BoostMarketbeat·Mar 25, 2026
- Denali Jumps, Pulling Regenxbio Higher, On Early FDA ApprovalYahoo Finance·Mar 25, 2026
- Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)Yahoo Finance·Mar 25, 2026
- Denali Therapeutics CEO: 2026 Pivotal With Hunter Syndrome FDA Decision and New TV Trial ReadoutsMarketbeat·Mar 19, 2026
- Denali Therapeutics Teases April 5 FDA Decision for Tivi as Launch Plans and Pipeline Catalysts BuildMarketbeat·Mar 15, 2026
- Denali Therapeutics (DNLI) Is Up 5.1% After Highlighting Tividenofusp Alfa Ahead Of FDA Decision – Has The Bull Case Changed?Yahoo Finance·Mar 13, 2026
- Assessing Denali Therapeutics (DNLI) Valuation After A Strong Year Of Share Price GainsYahoo Finance·Mar 13, 2026
All 22 articles loaded
Price Data
Open$19.22
Previous Close$18.92
Day High$20.00
Day Low$18.91
52 Week High$23.77
52 Week Low$12.58
52-Week Range
$12.58$23.77
$20.41
Fundamentals
Market Cap$3.1B
P/E Ratio—
EPS$-2.97
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume2.2M
Avg Volume (10D)—
Shares Outstanding158.7M
About Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—